Black Box Warning

A black box warning - formally called a 'boxed warning' by the FDA - is the strongest warning the agency can require for a prescription medicine. It appears at the very top of the prescribing information, enclosed in a black border, and signals that the medicine carries a significant risk of serious or life-threatening adverse effects. The FDA issues these warnings when post-marketing surveillance, clinical trials, or regulatory review identify a safety signal serious enough to warrant prominent disclosure to prescribers, pharmacists, and patients.

Boxed warnings cover a wide range of risks. Examples include the increased risk of suicidal thinking in young patients on SSRIs and other antidepressants; the risk of agranulocytosis with clozapine; the risk of QT prolongation and torsades de pointes with certain antiarrhythmics and antibiotics; the risk of severe hepatotoxicity with certain antidiabetic and antiepileptic medicines; the risk of cardiovascular and stroke events with non-selective NSAIDs and COX-2 inhibitors; the risk of birth defects with isotretinoin, valproate, and ACE inhibitors; the risk of stroke and increased mortality with antipsychotics in elderly dementia patients; and tendon rupture with fluoroquinolone antibiotics.

Clinically, the boxed warning is intended to prompt informed shared decision-making, not to forbid use. A medicine with a black box warning may still be the best option for a given patient - particularly in oncology and psychiatry where benefit can be substantial - but the warning must be discussed, documented, and balanced against alternatives. For some medicines, the FDA additionally requires a Risk Evaluation and Mitigation Strategy (REMS) program, which may include mandatory prescriber certification, patient registries, restricted distribution, and ongoing laboratory monitoring (e.g., the iPLEDGE program for isotretinoin or the clozapine REMS).

A common misconception is that a black box warning means a medicine is 'dangerous and should never be used.' In reality, hundreds of widely prescribed and life-saving medicines carry boxed warnings; the warning is a notice of significant risk, not a prohibition. Another misconception is that the warning automatically applies to all members of a medicine class - sometimes it does (all SSRIs carry the suicidal ideation warning for young patients), but sometimes it is medicine-specific. A third misconception is that the warning is static; the FDA can add, modify, or remove boxed warnings as evidence evolves.

Prescribers should review boxed warnings before initiating relevant medications, discuss them with patients in plain language, document the discussion in the medical record, and ensure any required monitoring (labs, ECGs, registry enrollment) is in place.